Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05731154
Other study ID # B-2110-715-304
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 22, 2021
Est. completion date July 25, 2022

Study information

Verified date February 2023
Source Seoul National University Bundang Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study was conducted to develop an AI solution to evaluate clinical activity score (CAS) of thyroid associated orbitopathy (TAO) using periocular selfie images taken by smartphones in patients with thyroid dysfunction. An AI solution to evaluate CAS in TAO was developed in previous retrospective study using periorbital digital images taken by DSLR camera in the studio. This AI solution will be adjusted to show its best performance with periocular selfie images taken by smartphones.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date July 25, 2022
Est. primary completion date July 18, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Patients with thyroid eye disease Exclusion Criteria: - Patients who have prior facial anomaly or surgery - Patients who cannot use smartphone camera app

Study Design


Intervention

Other:
taking periorbital selfie images using smartphones
taking periorbital selfie images using smartphones

Locations

Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do

Sponsors (2)

Lead Sponsor Collaborator
Seoul National University Bundang Hospital Thyroscope Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy for clinical activity score (CAS) of thyroid eye disease (TED) Accuracy of AI solution using smartphone selfie images for CAS of TED. baseline (this study has no intervention)
Primary Diagnostic accuracy for active thyroid eye disease Accuracy of AI solution using smartphone selfie images for active thyroid eye disease (TED) which is defined as 3 or more of clinical activity score baseline (this study has no intervention)
Secondary Accuracy for redness of eyelids Accuracy of AI solution using smartphone selfie images for redness of eyelids baseline (this study has no intervention)
Secondary Accuracy for redness of conjunctiva Accuracy of AI solution using smartphone selfie images for redness of conjunctiva baseline (this study has no intervention)
Secondary Accuracy for swelling of eyelids Accuracy of AI solution using smartphone selfie images for swelling of eyelids baseline (this study has no intervention)
Secondary Accuracy for swelling of conjunctiva Accuracy of AI solution using smartphone selfie images for swelling of conjunctiva baseline (this study has no intervention)
Secondary Accuracy for swelling of caruncle Accuracy of AI solution using smartphone selfie images for swelling of caruncle baseline (this study has no intervention)
See also
  Status Clinical Trial Phase
Completed NCT04583735 - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease Phase 4
Active, not recruiting NCT05002998 - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study Phase 4
Withdrawn NCT02422368 - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Phase 2/Phase 3
Completed NCT03298867 - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Phase 3
Recruiting NCT05987423 - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease Phase 3
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT05517447 - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Phase 3
Terminated NCT04737330 - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Phase 3
Recruiting NCT05517421 - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Phase 3
Recruiting NCT04311606 - Anti-VEGF Therapy for Acute Thyroid Eye Disease Phase 2
Recruiting NCT06106828 - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2) Phase 3
Recruiting NCT06021054 - A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED) Phase 3
Recruiting NCT06248619 - A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease Phase 3
Not yet recruiting NCT06413043 - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy N/A
Not yet recruiting NCT06401044 - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease Phase 1
Recruiting NCT06367517 - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation NCT05241626 - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting NCT05776121 - Study of ZB001 in Chinese Patients With Thyroid Eye Disease Phase 1
Recruiting NCT04359979 - Tamsulosin for Thyroid Lid Retraction N/A